Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Common Equity (2019 - 2026)

Maxcyte has reported Common Equity over the past 7 years, most recently at $171.5 million for Q4 2025.

  • Quarterly Common Equity fell 16.85% to $171.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $171.5 million through Dec 2025, down 16.85% year-over-year, with the annual reading at $171.5 million for FY2025, 16.85% down from the prior year.
  • Common Equity was $171.5 million for Q4 2025 at Maxcyte, down from $180.3 million in the prior quarter.
  • Over five years, Common Equity peaked at $264.1 million in Q3 2021 and troughed at $78.8 million in Q2 2021.
  • The 5-year median for Common Equity is $229.3 million (2023), against an average of $213.9 million.
  • Year-over-year, Common Equity surged 691.26% in 2021 and then fell 16.85% in 2025.
  • A 5-year view of Common Equity shows it stood at $262.9 million in 2021, then dropped by 3.4% to $254.0 million in 2022, then dropped by 8.58% to $232.2 million in 2023, then fell by 11.16% to $206.3 million in 2024, then fell by 16.85% to $171.5 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Common Equity are $171.5 million (Q4 2025), $180.3 million (Q3 2025), and $190.7 million (Q2 2025).